H.I.G. BioHealth Partners

Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in developing innovative drug delivery technologies aimed at treating various eye conditions. The company focuses on creating non-invasive products designed to replace traditional eye drops, offering sustained therapy for significant eye diseases such as glaucoma, dry eye, and allergies. Currently, ForSight VISION5 is in its second Phase 2 clinical study for its lead product, the Helios insert, which represents a significant advancement in ocular treatment options.

ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central pain processing mechanisms.

NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.